Company News-Gan & Lee

中文站

Careers | Investors | Patients and HCPS | Contact us

Careers Investors Patients and HCPS Contact us

Search

# Popular search #

Diabetes Oncology Medical Devices

Company News

Company News Exhibitions Activities

All news 2026 2025 2024 2023 2022 2021 2018

Gan & Lee Pharmaceuticals ADA 2026 Abstract Data Review | Multiple Metabolic Pipeline Research Results Presented at International Academic Conference
Gan & Lee 2026-06-11
Gan & Lee Showcases Multiple Innovative Research Achievements at the American Diabetes Association’s 86th Scientific Sessions
Gan & Lee 2026-06-10
Gan & Lee’s Once-Weekly Basal insulin GZR4 Injection Met the Primary Endpoint in the Pivotal Phase 3 SUPER-3 Trial and Demonstrated Superior HbA1c Reduction Versus Insulin Glargine U100
Gan & Lee 2026-06-05
52 weeks, 18.54% weight loss achieved! Gan & Lee Pharmaceuticals’Biweekly GLP-1 RA Bofanglutide injection Meets Primary Endpoints in Both a Pivotal Phase 3 Weight Management Trial in China and a pivotal Phase II study in the United States.
Gan & Lee 2026-06-04
Gan & Lee Receives Another Brazilian GMP Certification, Achieving Dual Compliance for Drug Substances and Finished Products
Gan & Lee 2026-06-01
Gan & Lee Attends the Multinational Diabetes Academic Conference 2026
Gan & Lee 2026-05-29

1 2 3 4 5 6 7 8 ... 23 24 >

Our websites

Gangan Technology

You are now leaving the Gan & Lee website.

The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.

Continue Back

Search

Subscribe